Private Management Group Inc. Decreases Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Private Management Group Inc. decreased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,181,665 shares of the company’s stock after selling 92,332 shares during the quarter. Private Management Group Inc. owned approximately 0.10% of Teva Pharmaceutical Industries worth $26,044,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. UMB Bank n.a. increased its stake in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the period. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $52,000. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $60,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Stock Up 1.0 %

TEVA stock opened at $17.23 on Thursday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business has a 50 day simple moving average of $20.03 and a 200-day simple moving average of $18.50. Teva Pharmaceutical Industries Limited has a twelve month low of $11.83 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 40.20%. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.